World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
25478
World Ranking
1500
National Ranking
756

Medicine

D-Index
82
Citations
25543
World Ranking
16081
National Ranking
8093

Craig L. Slingluff publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Craig L. Slingluff sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 381 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Craig L. Slingluff D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Craig L. Slingluff sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 82 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Craig L. Slingluff is affiliated with the University of Virginia in the United States and has contributed extensively to research in medicine, particularly focusing on oncology and immunology. Their work spans several fields of study including immunology and microbiology, as well as biochemistry, genetics, and molecular biology.

The scientist's research prominently addresses topics related to immunotherapy and immune responses, cancer immunotherapy and biomarkers, and cutaneous melanoma detection and management. Additional areas of study include CAR-T cell therapy research, vaccines and immunoinformatics approaches, immune cell function and interaction, and T-cell and B-cell immunology.

Craig L. Slingluff has published frequently in the following academic venues:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Annals of Surgical Oncology
  • Journal of Surgical Oncology

Notable recent publications by Slingluff include:

  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell
  • Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts, 2021, Cell Reports
  • Dissecting the treatment-naive ecosystem of human melanoma brain metastasis, 2022, Cell
  • Barriers to immune cell infiltration in tumors, 2023, Journal for ImmunoTherapy of Cancer
  • Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma, 2021, Journal for ImmunoTherapy of Cancer

Throughout their career, Slingluff has collaborated frequently with several coauthors, including:

  • Kevin Lynch
  • Max O. Meneveau
  • Ileana S. Mauldin
  • Elizabeth Gaughan
  • Walter C. Olson

Best Publications

  • Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

    Nadeem Riaz;Jonathan J. Havel;Vladimir Makarov;Alexis Desrichard

  • Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

    David H. Munn;Madhav D. Sharma;Jeffrey R. Lee;Kanchan G. Jhaver

  • Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

    Helena Harlin;Yuru Meng;Amy C. Peterson;Yuanyuan Zha

  • Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines

    Andrea L. Cox;Jonathan Skipper;Ye Chen;Robert A. Henderson

  • Immunotype and Immunohistologic Characteristics of Tumor Infiltrating Immune Cells are Associated with Clinical Outcome in Metastatic Melanoma

    Gulsun Erdag;Jochen T. Schaefer;Jochen T. Schaefer;Mark E. Smolkin;Donna H. Deacon

  • An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

    J C Skipper;R C Hendrickson;P H Gulden;V Brichard

  • Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

    Craig L. Slingluff;Gina R. Petroni;Galina V. Yamshchikov;Donna L. Barnd

  • The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

    Craig L. Slingluff

  • Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

    Jeffrey S Weber;Geoff Gibney;Ryan J Sullivan;Jeffrey A Sosman

  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Catherine S. Grasso;Catherine S. Grasso;Jennifer Tsoi;Mykola Onyshchenko;Gabriel Abril-Rodriguez

  • Impact of Patient Distance to Radiation Therapy on Mastectomy Use in Early-Stage Breast Cancer Patients

    Anneke T. Schroen;David R. Brenin;Maria D. Kelly;William A. Knaus

  • Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-α

    Thomas Tüting;Cara C. Wilson;Dina M. Martin;Yvette L. Kasamon

  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

    T L Darrow;C L Slingluff;H F Seigler

  • Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

    Craig L. Slingluff;Galina Yamshchikov;Patrice Neese;Holly Galavotti

  • Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

    Howard L Kaufman;Carl E Ruby;Tasha Hughes;Craig L Slingluff

  • Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127–35 peptide: Implications for peptide vaccines

    Laurence H. Brinckerhoff;Vladimir V. Kalashnikov;Lee W. Thompson;Galina V. Yamshchikov

  • Lethal "thin" malignant melanoma. Identifying patients at risk.

    Craig L. Slingluff;Robin T. Vollmer;Douglas S. Reintgen;Hilliard F. Seigler

  • Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

    Victor H. Engelhard;Anthony B. Rodriguez;Ileana S. Mauldin;Amber N. Woods

  • Surgical Management of Regional Lymph Nodes in Patients with Melanoma Experience with 4682 Patients

    Craig L. Slingluff;Katrina R. Stidham;William M. Ricci;Wilma E. Stanley

  • Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

    Craig L. Slingluff;Gina R. Petroni;Walter C. Olson;Mark E. Smolkin

  • Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells ROLE OF BRAF MUTATION AND FIBROBLAST GROWTH FACTOR SIGNALING

    Jonathan T. Huntington;Janiel M. Shields;Channing J. Der;Colby A. Wyatt

Frequent Co-Authors

Victor H. Engelhard
Victor H. Engelhard University of Virginia
Hilliard F. Seigler
Hilliard F. Seigler Duke University
Donald F. Hunt
Donald F. Hunt University of Virginia
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Jeffrey Shabanowitz
Jeffrey Shabanowitz University of Virginia
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Ena Wang
Ena Wang Toro bio
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
F. Stephen Hodi
F. Stephen Hodi Harvard University
Walter J. Urba
Walter J. Urba Providence Portland Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens doors to a variety of healthcare and research careers. Many students complement their immunology background with nursing degrees to expand their practical skills and clinical opportunities.

For those interested in advanced clinical roles, accelerated nurse practitioner programs provide a fast-track option to becoming a licensed practitioner. These programs are designed for professionals seeking to quickly transition into nurse practitioner roles with specialized patient care expertise.

If you are new to nursing but have a science-related degree, exploring online RN programs for non nurses can be a great way to enter the nursing field. These programs accommodate students without a traditional nursing background and emphasize flexible online learning formats.

On the other hand, some individuals may prefer to start with foundational nursing education. Options like the easiest accelerated nursing programs to get into offer streamlined access to obtaining a Bachelor of Science in Nursing degree with minimal barriers to entry.

Similarly, LPN programs easy to get into provide an accessible pathway to become a Licensed Practical Nurse. These programs often require less time and prerequisites, making them ideal for those seeking to quickly join the healthcare workforce.

Best Scientists Citing Craig L. Slingluff

Trending Scientists

Recently Published Articles